Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination

Chih Wen Tseng, Archana Monie, Chao Yi Wu, Bruce Huang, Mei Cheng Wang, Chien Fu Hung, T. C. Wu

Research output: Contribution to journalArticlepeer-review

Abstract

There is an urgent need to develop new innovative therapies for the control of cancer. Antigen-specific immunotherapy and the employment of proteasome inhibitors have emerged as two potentially plausible approaches for the control of cancer. In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 E7 antigen (CRT/E7) with the proteasome inhibitor, bortezomib, for their ability to generate E7-specific immune responses and antitumor effects in vaccinated mice. We found that the combination of treatment with bortezomib and CRT/E7(detox) DNA generated more potent E7-specific CD8+ T cell immune responses and better therapeutic effects against TC-1 tumors in tumor-bearing mice compared to monotherapy. Furthermore, we found that treatment with bortezomib led to increased apoptosis of TC-1 tumor cells and could render the TC-1 tumor cells more susceptible to lysis by E7-specific CD8+ T cells. Our data have significant implications for future clinical translation.

Original languageEnglish (US)
Pages (from-to)899-908
Number of pages10
JournalJournal of Molecular Medicine
Volume86
Issue number8
DOIs
StatePublished - Aug 2008

Keywords

  • Bortezomib
  • Calreticulin (CRT)
  • DNA vaccine
  • E7
  • Human papillomavirus (HPV)

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination'. Together they form a unique fingerprint.

Cite this